Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:SYNNYSE:TRP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shsTRPTC Energy$49.84-0.1%$48.79$37.07▼$51.34$51.81B0.782.50 million shs1.51 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%TRPTC Energy-0.31%+0.04%-0.67%+12.45%+30.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationSYNSynthetic BiologicsN/AN/AN/AN/AN/AN/AN/AN/ATRPTC Energy3.5243 of 5 stars2.42.01.70.82.81.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSYNSynthetic Biologics 0.00N/AN/AN/ATRPTC Energy 2.83Moderate Buy$62.0024.40% UpsideCurrent Analyst Ratings BreakdownLatest LOGP, SYN, TRP, and RBD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025TRPTC EnergyCibc World MktsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/2/2025TRPTC EnergyCIBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Sector Outperform4/4/2025TRPTC EnergyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ATRPTC Energy$13.89B3.73$5.63 per share8.85$25.19 per share1.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ATRPTC Energy$3.43B$3.0315.3817.744.3429.40%12.12%3.54%8/7/2025 (Estimated)Latest LOGP, SYN, TRP, and RBD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025TRPTC Energy$0.70$0.66-$0.04$0.65$2.57 billion$1.78 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthSYNSynthetic BiologicsN/AN/AN/AN/AN/ATRPTC Energy$2.364.74%+2.46%77.89%1 YearsLatest LOGP, SYN, TRP, and RBD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025TRPTC Energyquarterly$0.61424.9%6/30/20256/30/20257/31/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSYNSynthetic BiologicsN/A4.144.14TRPTC Energy1.560.551.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSYNSynthetic Biologics74.38%TRPTC Energy83.13%Insider OwnershipCompanyInsider OwnershipSYNSynthetic Biologics2.15%TRPTC EnergyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableTRPTC Energy7,4801.04 billionN/AOptionableLOGP, SYN, TRP, and RBD HeadlinesRecent News About These CompaniesUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in TC Energy Co. (NYSE:TRP)May 29 at 4:30 AM | marketbeat.comValue Partners Investments Inc. Takes $245,000 Position in TC Energy Co. (NYSE:TRP)May 27 at 5:54 AM | marketbeat.comPublic Employees Retirement System of Ohio Purchases 272,457 Shares of TC Energy Co. (NYSE:TRP)May 27 at 5:18 AM | marketbeat.comWhat is Zacks Research's Estimate for TC Energy Q2 Earnings?May 27 at 1:25 AM | americanbankingnews.comZacks Research Has Bearish Outlook for TC Energy Q2 EarningsMay 27 at 1:18 AM | marketbeat.com3 TSX Dividend Payers Ready to Reward Investors NowMay 26 at 9:35 PM | msn.comMackenzie Financial Corp Lowers Stock Position in TC Energy Co. (NYSE:TRP)May 26 at 7:24 AM | marketbeat.comCenterstone Investors LLC Sells 32,808 Shares of TC Energy Co. (NYSE:TRP)May 26 at 6:09 AM | marketbeat.comZacks Research Forecasts TC Energy's Q1 Earnings (NYSE:TRP)May 25, 2025 | marketbeat.comParr Mcknight Wealth Management Group LLC Takes $2.51 Million Position in TC Energy Co. (NYSE:TRP)May 25, 2025 | marketbeat.comTC Energy Co. (NYSE:TRP) Shares Sold by Centerstone Investors LLCMay 25, 2025 | marketbeat.comBurgundy Asset Management Ltd. Sells 48,169 Shares of TC Energy Co. (NYSE:TRP)May 25, 2025 | marketbeat.comTwinbeech Capital LP Takes $558,000 Position in TC Energy Co. (NYSE:TRP)May 25, 2025 | marketbeat.comNomura Holdings Inc. Purchases Shares of 5,743 TC Energy Co. (NYSE:TRP)May 25, 2025 | marketbeat.comZacks Research Brokers Lift Earnings Estimates for TC EnergyMay 25, 2025 | americanbankingnews.comUS Capital Advisors Boosts Earnings Estimates for TC EnergyMay 24, 2025 | marketbeat.comTC Energy Co. (NYSE:TRP) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT CorpMay 24, 2025 | marketbeat.comUSS Investment Management Ltd Grows Holdings in TC Energy Co. (NYSE:TRP)May 24, 2025 | marketbeat.comTC Energy Q2 EPS Forecast Reduced by US Capital AdvisorsMay 23, 2025 | marketbeat.comTC Energy Co. (NYSE:TRP) Shares Sold by Zurich Insurance Group Ltd FIMay 23, 2025 | marketbeat.comUS Capital Advisors Forecasts TC Energy FY2027 EarningsMay 23, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLOGP, SYN, TRP, and RBD Company DescriptionsSynthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.TC Energy NYSE:TRP$49.84 -0.05 (-0.10%) Closing price 03:59 PM EasternExtended Trading$49.85 +0.01 (+0.02%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TC Energy Corporation operates as an energy infrastructure company in North America. It operates through five segments: Canadian Natural Gas Pipelines; U.S. Natural Gas Pipelines; Mexico Natural Gas Pipelines; Liquids Pipelines; and Power and Energy Solutions. The company builds and operates a network of 93,600 kilometers of natural gas pipelines, which transports natural gas from supply basins to local distribution companies, power generation plants, industrial facilities, interconnecting pipelines, LNG export terminals, and other businesses. It also has regulated natural gas storage facilities with a total working gas capacity of 532 billion cubic feet. In addition, it has approximately 4,900 kilometers of liquids pipeline system that connects Alberta crude oil pipeline to refining markets in Illinois, Oklahoma, Texas, and the United States Gulf Coast. Further, the company owns or has interests in power generation facilities with approximately 4,600 megawatts; and owns and operates approximately 118 billion cubic feet of non-regulated natural gas storage facilities in in Alberta, Ontario, Québec, and New Brunswick. The company was formerly known as TransCanada Corporation and changed its name to TC Energy Corporation in May 2019. TC Energy Corporation was founded in 1951 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
